Regenerative Medicine in Aesthetics: Current Evidence

Last updated: 5 August 2026

What is regenerative aesthetics?

Regenerative medicine in the context of aesthetics refers to treatments that harness the body’s own biological processes to repair, regenerate, and rejuvenate tissue. Unlike traditional aesthetic treatments that add external materials (such as fillers) or modify existing structures (such as botulinum toxin), regenerative approaches stimulate the body’s intrinsic healing and renewal mechanisms to produce lasting improvements in tissue quality.

We are committed to offering only treatments with a credible evidence base. The field of regenerative aesthetics is exciting and prone to exaggerated claims. This article provides an honest, evidence-based overview of the current state of regenerative treatments, clearly distinguishing between what is proven, what is promising, and what remains speculative.

Platelet-rich plasma (PRP)

PRP is the most established regenerative treatment in aesthetics. It involves drawing a small volume of the patient’s blood (typically 10–30ml), processing it in a centrifuge to concentrate the platelet fraction, and reinjecting the platelet-rich concentrate into the target area.

The Science

Platelets contain over 300 biologically active proteins, including growth factors critical for tissue repair:

• PDGF (Platelet-Derived Growth Factor): Stimulates fibroblast proliferation and collagen synthesis.
• TGF-beta (Transforming Growth Factor): Promotes extracellular matrix production and wound healing.
• VEGF (Vascular Endothelial Growth Factor): Stimulates angiogenesis (new blood vessel formation), improving tissue perfusion.
• EGF (Epidermal Growth Factor): Promotes keratinocyte proliferation and epidermal regeneration.
• IGF-1 (Insulin-like Growth Factor): Stimulates cell growth and differentiation.

Clinical Evidence

A 2023 systematic review in the Aesthetic Surgery Journal, analysing 45 randomised controlled trials, concluded that PRP has moderate to strong evidence for skin rejuvenation (improvement in fine lines, texture, and skin quality after 3 sessions), acne scarring (30–50% improvement when combined with microneedling), and hair restoration (increased hair density by 15–30% in androgenetic alopecia after 3–4 sessions at monthly intervals). The evidence was weaker for dark circles and pigmentation.

Limitations

PRP quality varies significantly based on preparation method. Different centrifuge protocols produce different platelet concentrations, and standardisation remains an ongoing challenge. Also, individual variation in platelet quality and growth factor content means that results can be unpredictable.

Polynucleotides (PN)

Polynucleotide therapy has emerged as one of the most promising regenerative treatments in recent years. Derived from purified DNA fragments (typically from salmon or trout sperm cells), polynucleotides are injectable biostimulators that promote tissue regeneration through multiple pathways.

The Science

Polynucleotides work through several mechanisms documented in Aesthetic Plastic Surgery (2023):

• Fibroblast stimulation: PN binds to purinergic receptors on fibroblasts, stimulating proliferation and collagen/elastin production.
• Free radical scavenging: PN acts as a molecular “sponge” for reactive oxygen species. This provides antioxidant protection.
• Anti-inflammatory action: Reduces levels of pro-inflammatory cytokines (IL-6, TNF-alpha) in treated tissue.
• Hydration: The gel-like consistency of PN formulations provides immediate tissue hydration alongside longer-term regenerative effects.

Clinical Evidence

Clinical trials have demonstrated significant improvements in skin elasticity (25–35% improvement measured by cutometry after 3 sessions), skin hydration (40–50% improvement in corneometry scores), fine wrinkle depth (20–30% reduction), and under-eye skin quality (reduced dark circles and crepiness). A multicentre study published in the Journal of Cosmetic Dermatology (2024) showed that the effects of polynucleotide treatment persisted for 6–9 months post-treatment, suggesting genuine tissue regeneration rather than merely temporary filling or hydration.

Exosome Therapy

Exosomes represent the newest frontier in regenerative aesthetics. These nano-sized vesicles (30–150nm) are secreted by cells and contain a cargo of proteins, lipids, mRNAs, and microRNAs that modulate cellular behaviour in recipient cells.

The Science

Exosomes derived from mesenchymal stem cells (MSC-exosomes) have been shown in laboratory studies to stimulate fibroblast activity and collagen production, promote angiogenesis and wound healing, modulate inflammatory responses, and transfer regenerative signalling molecules between cells. Research published in Stem Cells Translational Medicine (2023) demonstrated that MSC-exosomes applied to aged human skin in an ex vivo model increased type I collagen production by 200% and reduced MMP-1 expression by 60%.

Clinical Reality

Despite the exciting preclinical data, the clinical evidence for exosome therapy in aesthetics is still in its early stages. Key considerations include the limited number of well-designed clinical trials (most evidence is from case series and uncontrolled studies), significant variability in exosome products (source, concentration, cargo composition, and quality control differ widely), no standardised manufacturing processes or regulatory frameworks in the UK for cosmetic exosome products, and the need for further long-term safety data.

We follow exosome research with great interest but maintain that current evidence does not yet support routine clinical use. We will introduce exosome-based treatments when the evidence reaches the standard we require for patient recommendation.

Growth factor therapies

Topical and injectable growth factor preparations represent another regenerative approach. These may be derived from human fibroblast conditioned media, plant stem cell extracts, or recombinant (laboratory-synthesised) growth factors.

Evidence Assessment

A systematic review in Dermatologic Surgery (2023) found moderate evidence for topical EGF and TGF-beta in improving skin texture and wound healing, limited but positive evidence for fibroblast-conditioned media in skin rejuvenation, and insufficient evidence for plant stem cell extracts (marketing claims far outstrip scientific evidence for this category).

Autologous fat transfer

Fat transfer, harvesting fat from one area of the body and reinjecting it into the face, has regenerative properties beyond simple volume replacement. Adipose tissue is rich in adipose-derived stem cells (ADSCs) that release growth factors, cytokines, and exosomes promoting tissue regeneration.

Clinical evidence published in Plastic and Reconstructive Surgery (2023) confirms that fat grafting improves skin quality in the recipient area (texture, pigmentation, pore size), with benefits persisting beyond the expected filler lifespan, consistent with a regenerative mechanism rather than purely volumetric correction.

Evaluating regenerative claims

The regenerative medicine field is unfortunately rife with exaggerated marketing claims. The evidence supports patients evaluate regenerative treatments using these criteria:

• Publication quality: Has the treatment been evaluated in peer-reviewed, randomised controlled trials? Case reports and uncontrolled studies are insufficient to establish efficacy.
• Sample size: Studies with fewer than 30 participants should be interpreted with caution.
• Follow-up duration: Regenerative treatments should demonstrate lasting effects. Short follow-up periods (less than 6 months) may not distinguish genuine tissue regeneration from temporary effects.
• Objective outcomes: Validated measurement tools (histology, elastometry, TEWL measurement) are more reliable than subjective patient or physician ratings alone.
• Independent verification: Has the evidence been reproduced by researchers independent of the product manufacturer?

The future of regenerative aesthetics

Several areas of active research hold significant promise. Induced pluripotent stem cell (iPSC) derived factors may offer personalised regenerative treatments tailored to individual biology. Gene therapy approaches targeting specific ageing pathways (senolytic therapies) could address cellular senescence directly. Bioprinted skin scaffolds seeded with autologous cells may eventually provide true skin regeneration for scarring and severe photodamage.

Key Takeaways

• PRP and polynucleotides have the strongest current evidence base among regenerative aesthetic treatments
• Exosomes show exciting preclinical promise but lack sufficient clinical evidence for routine use
• Critical evaluation of marketing claims is essential in this rapidly evolving field
• Genuine regenerative treatments should demonstrate lasting tissue changes, not just temporary improvements
• An ethical practitioner will clearly distinguish between proven, promising, and speculative treatments